Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib
A panel of experts compare the toxicity profiles of abemaciclib and ribociclib.
EP: 1.Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer
EP: 2.Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial
EP: 3.Outcomes from NATALEE and MonarchE
EP: 4.Sequencing Considerations with CDK4/6 Inhibitors Used in Earlier Treatment
Now Viewing
EP: 5.Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib
EP: 6.Dr Dempsey Shares How the Type of Endocrine Therapy Can Impact Toxicities Seen in Her Patients
EP: 7.Hope Rugo, MD Shares Her Management Strategy for GI Toxicities with Abema
EP: 8.Dr. O’Shaughnessy Shares Her Management Strategy for Hematologic Toxicities with Ribociclib
EP: 9.Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors
EP: 10.How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor
EP: 11.Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors
EP: 12.Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies
EP: 13.ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer
Video content above is prompted by the following questions:
- What are the primary differences in the toxicity profiles of abemaciclib and ribociclib when used in the adjuvant setting, and how are these prioritized when selecting a CDK4/6 inhibitor?
- Discuss the recent publication of long-term patient-reported outcomes with adjuvant abemaciclib.
Related Videos
Related Content
